Shares of Valeant Pharmaceuticals surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. The embattled pharma stock continues to polarize investors, but its recent recovery is starting to gain momentum. As we approach the New Year, it is time to ask: is Valeant officially back?
Shares are still a long way from their highs of mid-2015, but the stock has climbed about 90% since the beginning of November. Valeant’s run comes as investors gear up for the company to begin sales of its new glaucoma treatment, Vyzulta, which should start this month.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Shares of Valeant Pharmaceuticals surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. The embattled pharma stock continues to polarize investors, but its recent recovery is starting to gain momentum. As we approach the New Year, it is time to ask: is Valeant officially back?
Shares are still a long way from their highs of mid-2015, but the stock has climbed about 90% since the beginning of November. Valeant’s run comes as investors gear up for the company to begin sales of its new glaucoma treatment, Vyzulta, which should start this month.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>